

# Protocol for Respiratory Syncytial Virus (RSV) Vaccine

## 1. What's New

- A. The West Coast Health Alliance (WCHA) is issuing immunization recommendations for the 2025-2026 respiratory virus season. These recommendations are informed by trusted national medical organizations, including [American Academy of Pediatrics](#) (AAP), the [American College of Obstetricians and Gynecologists](#) (ACOG), and the [American Academy of Family Physicians](#) (AAFP). The WCHA believes that all recommended immunizations should be accessible to the people of our states.

## 2. Immunization Protocol

- A. Administer a single lifetime dose, IM, RSV vaccine to all adults ages 75 years and older.
- B. Administer a single lifetime dose, IM, RSV vaccine to persons ages 50 through 74 years of age if they are at increased risk of severe RSV disease, as described in Section 4.
- C. Administer a single lifetime dose, IM, RSV vaccine to pregnant patients at 32-36 weeks gestational age.
- D. RSV vaccine may be given with all ACIP- and WCHA-recommended adult vaccinations, including COVID-19 vaccines.

## 3. Vaccine Schedule <sup>1</sup>

	RSV immunization
<b>Pregnancy</b>	32 through 36 weeks gestational age <sup>1</sup>
<b>Adults</b>	All ≥ 75 years <sup>2</sup> All 50 through 74 years with risk factors <sup>2,3</sup>

<sup>1</sup> Either immunization with nirsevimab/clesrovimab **or maternal RSV vaccination** is indicated to protect infants from severe RSV infection.

<sup>2</sup> Adult RSV immunization recommendations are currently for a single lifetime dose. Those who have previously received a dose do not need a second dose.

<sup>3</sup> See **Section 4** for additional information on risk factors for severe RSV disease in adults 50-74 years.

## 4. Additional Considerations for Use

- A. For additional information on risk factors for severe RSV disease in adults 50 through 74 years of age, see: <https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.html>.

## 5. Pregnancy and Lactation <sup>2-4</sup>

- A. It is unknown if RSV vaccines are excreted in human milk.
- B. See current prescribing information additional considerations regarding pregnancy and lactation.

## 6. Warnings and Precautions <sup>2-4</sup>

- A. Individuals with acute, moderate, or severe illness with or without fever should delay immunization until symptoms have improved.
- B. Individuals with an immunocompromising condition may experience a diminished immune response to the vaccine.

## Protocol for Respiratory Syncytial Virus (RSV) Vaccine

- C. See current prescribing information for more details about warnings, precautions, formulation, and contents.

### 7. Contraindications <sup>1-3</sup>

- A. Severe allergic reaction (e.g., anaphylaxis) to a previous dose or to any vaccine component.
- B. See current prescribing information for details about contraindications.

### 8. Storage and Handling <sup>1-3</sup>

- A. Store medications according to [OAR 855-041-1036](#).
- B. See current prescribing information for additional details about storage and handling.

### 9. References

1. West Coast Health Alliance 2025-2026 Recommendations for Respiratory Vaccines. Available at: <https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/VACCINESIMMUNIZATION/GETTINGIMMUNIZED/Documents/2025-26-Respiratory-Virus-Vaccine-Recommendations.pdf>
2. Abrysvo™. [Package insert]. October 2023. <https://www.fda.gov/media/168889/download>
3. Arexvy™. [Package insert]. June 2024. <https://www.fda.gov/media/167805/download?attachment>
4. mRESVIA®. [Package insert]. October 2024. <https://www.fda.gov/media/179005/download?attachment>